New research indicates that individuals who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt traditional lifestyle programs.
Published data in a leading medical journal demonstrates that while obese individuals can lose a large proportion of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these drugs need to be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery means a reversion to starting mass in about 18 months.
Weighing Approaches
The analysis, which reviewed dozens of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.
Scientists note that individuals who shed pounds through dieting typically have a more gradual creep back—around 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Nutrition scientists suggest the way of the drugs explains the amplified rebound.
The injections copy a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of the hormone concentrations far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Issue?
Health authorities recommend the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the likelihood of weight regain, the treatment might need to be ongoing.
This opinion is echoed by drug manufacturers, who state that the results "highlight the persistent character of obesity," akin to managing conditions like high blood pressure.
User Accounts
Users who have come off the jabs explain a powerful return of hunger.
"I experienced something that goes on and I was suddenly starving," recalled a patient.
The struggle is compounded if individuals have not established permanent lifestyle or habit modifications during treatment.
Widespread Use
Survey data show that a significant number of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts emphasize that while these medications are powerful agents for weight loss, they are not a standalone cure and lasting health benefits hinges on ongoing lifestyle changes.
